Page 185 - Drug Class Review
P. 185
Drug Effectiveness Review Project
Drugs Authors: Rogers et al. 44 To study the efficacy and safety of DON for patients with mild to moderate AD Setting: Multi-center (20 sites) placebo donepezil donepezil N/A 10 mg/d 5 mg/d 24 weeks 24 weeks 24 weeks 162 157 154 Men and women of any race > 50 yrs old diagnosed with uncomplicated AD; probable AD diagnosed by NINCDS guidelines; MMSE score of 10 – 26; CDR score of 1 or 2 Patients with evidence of insulin dependent diabetes, mellitus or other endocrine disorders; asthma, obstructive pulmonary disease or clinically significant uncontrolled gastrointest
Alzheimer Year: 1998 Country: US Eisai Inc. Study design: RCT Sample size: 473
Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
